Detalles de la búsqueda
1.
Comparison of two-year treatment adherence, persistence, discontinuation, reinitiation, and switching between psoriasis patients treated with ixekizumab or secukinumab in real-world settings.
J Am Acad Dermatol
; 86(3): 581-589, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34252464
2.
Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab.
J Am Acad Dermatol
; 82(4): 927-935, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-31712178
3.
Prevalence, characteristics, and costs of diagnosed homocystinuria, elevated homocysteine, and phenylketonuria in the United States: a retrospective claims-based comparison.
BMC Health Serv Res
; 20(1): 183, 2020 Mar 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32143624
4.
Healthcare resource utilization and costs before and after lacosamide initiation as adjunctive therapy among patients with epilepsy in the United States.
Epilepsy Behav
; 99: 106331, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31399339
5.
Optimal site of care for administration of extended half-life respiratory syncytial virus (RSV) antibodies to infants in the United States (US).
Vaccine
; 41(40): 5820-5824, 2023 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37586957
6.
Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months.
Pharmacoecon Open
; 6(6): 871-880, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36155891
7.
Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings.
J Med Econ
; 25(1): 741-749, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35615978
8.
Increased health care costs associated with new persistent opioid use after major surgery in opioid-naive patients.
J Manag Care Spec Pharm
; 27(6): 760-771, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33624534
9.
Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months.
Dermatol Ther (Heidelb)
; 11(6): 2133-2145, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34652590
10.
Corticosteroid dosing and opioid use are high in patients with SLE and remain elevated after belimumab initiation: a retrospective claims database analysis.
Lupus Sci Med
; 7(1)2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33361460
11.
Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab.
Patient Prefer Adherence
; 14: 517-527, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32210539
12.
The Economic Burden of End-Organ Damage Among Medicaid Patients with Sickle Cell Disease in the United States: A Population-Based Longitudinal Claims Study.
J Manag Care Spec Pharm
; 26(9): 1121-1129, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32597290
13.
Comparison of Health Care Costs Among Patients with Psoriasis Initiating Ixekizumab, Secukinumab, or Adalimumab.
J Manag Care Spec Pharm
; 25(12): 1366-1376, 2019 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-31778621
14.
Health Care Burden Associated with Outpatient Opioid Use Following Inpatient or Outpatient Surgery.
J Manag Care Spec Pharm
; 25(9): 973-983, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31313621
15.
Loss of Glycogen Debranching Enzyme AGL Drives Bladder Tumor Growth via Induction of Hyaluronic Acid Synthesis.
Clin Cancer Res
; 22(5): 1274-83, 2016 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26490312
Resultados
1 -
15
de 15
1
Próxima >
>>